| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2004.00.1990 |
| P698 | PubMed publication ID | 16275937 |
| P50 | author | Joan Carles Galcerán | Q38546550 |
| P2093 | author name string | Luis Paz-Ares | |
| Francisco Lobo | |||
| Hernán Cortés-Funes | |||
| Antonio López-Pousa | |||
| Vicente Valentí | |||
| Antonio Antón | |||
| Dolores Isla | |||
| Andrés Cervantes | |||
| Ricardo Hitt | |||
| Miguel A Sánchez | |||
| Javier Martínez-Trufero | |||
| Alfredo Rizo | |||
| Carlos Chaib | |||
| Cinta Pallarés | |||
| Joaquín Belón | |||
| Juan L Martí | |||
| M Eugenia Vega | |||
| Pedro Pastor | |||
| Vicente Escrig | |||
| P433 | issue | 34 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | fluorouracil | Q238512 |
| cisplatin | Q412415 | ||
| paclitaxel | Q423762 | ||
| chemotherapy | Q974135 | ||
| chemoradiotherapy | Q5090613 | ||
| P304 | page(s) | 8636-8645 | |
| P577 | publication date | 2005-11-07 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer | |
| P478 | volume | 23 |
| Q47253569 | A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck |
| Q36727111 | A Phase II Clinical Trial of Concurrent Helical Tomotherapy plus Cetuximab Followed by Adjuvant Chemotherapy with Cisplatin and Docetaxel for Locally Advanced Nasopharyngeal Carcinoma |
| Q36022400 | A Phase II Study of Docetaxel, Cisplatin and 5- Fluorouracil (TPF) In Patients with Locally Advanced Head and Neck Carcinomas. |
| Q91843439 | A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma |
| Q33491298 | A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck |
| Q37322374 | A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. |
| Q40351640 | A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors |
| Q46991010 | A phase I trial of docetaxel based induction and concomitant chemotherapy in patients with locally advanced head and neck cancer |
| Q34539055 | A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007. |
| Q34498577 | A single centre experience with sequential and concomitant chemoradiotherapy in locally advanced stage IV tonsillar cancer |
| Q38850017 | ACR Appropriateness Criteria(®) Locoregional therapy for resectable oropharyngeal squamous cell carcinomas |
| Q48240243 | AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma. |
| Q37134458 | Advances in radiation therapy of head and neck cancer |
| Q80207264 | Altered fractionation: a fractional benefit? |
| Q41613065 | Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03. |
| Q37342399 | Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number |
| Q37338154 | Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion |
| Q37739426 | Chemotherapy regimens and treatment protocols for laryngeal cancer. |
| Q37495292 | Class III beta-tubulin, but not ERCC1, is a strong predictive and prognostic marker in locally advanced head and neck squamous cell carcinoma. |
| Q92433627 | Clinical features of 4 patients who underwent neoadjuvant chemotherapy for the locally advanced penile cancer |
| Q34511068 | Combination of taxanes, cisplatin and fluorouracil as induction chemotherapy for locally advanced head and neck cancer: a meta-analysis |
| Q36752037 | Combined modality treatment of laryngeal squamous cell carcinoma |
| Q84588057 | Combined therapy for thyroid squamous cell carcinoma |
| Q30422986 | Combined-modality treatment improved outcome in sinonasal undifferentiated carcinoma: single-institutional experience of 21 patients and review of the literature |
| Q89514089 | Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein-Barr virus DNA level |
| Q38196452 | Comprehensive treatment of squamous cell cancer of head and neck: Chinese expert consensus 2013. |
| Q43209150 | Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. |
| Q38139996 | Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer. |
| Q44740471 | Cost effectiveness of neoadjuvant chemotherapy in locally advanced operable head and neck cancer followed by surgery and postoperative radiotherapy: a Markov model-based decision analysis. |
| Q50114523 | Current and future directions in the treatment of squamous cell carcinoma of the head and neck: multidisciplinary symposium on head and neck cancer |
| Q24200362 | De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma |
| Q37202758 | Docetaxel in the management of patients with head and neck squamous cell carcinoma |
| Q37052798 | Docetaxel in the treatment of squamous cell carcinoma of the head and neck |
| Q34257367 | Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group [...] |
| Q37334815 | Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. |
| Q84803539 | EDITORIAL: Evidence‐based management of oropharyngeal cancer |
| Q58775208 | Early metabolic 18F-FDG PET/CT response of locally advanced squamous-cell carcinoma of head and neck to induction chemotherapy: A prospective pilot study |
| Q41646543 | Effect of induction chemotherapy on survival in locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: Single center experience. |
| Q38963962 | Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials. |
| Q61758596 | Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma |
| Q37791776 | Empowering induction therapy for locally advanced head and neck cancer |
| Q53193306 | Evaluation of overall tumor cellularity after neoadjuvant chemotherapy in patient with locally advanced hypopharyngeal cancer. |
| Q42930943 | Evaluation of the genotoxicity of cisplatin, paclitaxel and 5-fluorouracil combined treatment in the Drosophila wing-spot test |
| Q50660925 | Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with concurrent weekly cisplatin chemoradiotherapy for locally advanced head and neck squamous cell carcinoma. |
| Q43650000 | Feasibility and tolerance of sequential chemoradiotherapy in squamous cell carcinoma of the head and neck |
| Q33393655 | Feasibility, toxicity, and efficacy of short induction chemotherapy of docetaxel plus cisplatin or carboplatin (TP) followed by concurrent chemoradio-therapy for organ preservation in advanced cancer of the hypopharynx, larynx, and base of tongue. E |
| Q26778990 | Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion |
| Q37703390 | Galectin-7 as a potential predictive marker of chemo- and/or radio-therapy resistance in oral squamous cell carcinoma |
| Q54152939 | Head and neck cancer |
| Q37271937 | Head and neck cancer: an evolving treatment paradigm |
| Q50687479 | High-dose cisplatin concurrent to conventionally delivered radiotherapy is associated with unacceptable toxicity in unresectable, non-metastatic stage IV head and neck squamous cell carcinoma. |
| Q62071383 | How does TPF improve survival over PF? |
| Q84016685 | How does TPF improve survival over PF? |
| Q35188885 | Immunomodulated anterior chemotherapy followed by concurrent chemoradiotherapy in locally advanced tongue cancer: An Institutional experience |
| Q42541156 | Implications of therapy-induced selective autophagy on tumor metabolism and survival |
| Q41926329 | Increasing the therapeutic efficacy of docetaxel for cutaneous squamous cell carcinoma through the combined inhibition of phosphatidylinositol 3-kinase/AKT signalling and autophagy. |
| Q52596125 | Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Role, Controversy, and Future Directions. |
| Q33561959 | Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial |
| Q36977615 | Induction chemotherapy for head and neck squamous cell carcinomas (SCCHN). |
| Q36731539 | Induction chemotherapy for squamous cancer of the head and neck |
| Q36864470 | Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation |
| Q35652246 | Induction chemotherapy with concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced squamous cell carcinoma of head and neck: a meta-analysis |
| Q35605411 | Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study |
| Q34991804 | Induction chemotherapy with paclitaxel, ifosfamide, and cisplatin followed by concurrent chemoradiotherapy for unresectable locally advanced head and neck cancer |
| Q50193583 | Induction chemotherapy with the EXTREME regimen in frail patients with locally advanced head and neck squamous cell carcinoma |
| Q38800347 | Inhibition of heme oxygenase-1 enhances the chemosensitivity of laryngeal squamous cell cancer Hep-2 cells to cisplatin |
| Q24235229 | Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy |
| Q24235245 | Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy |
| Q35606525 | Lactate dehydrogenase B is associated with the response to neoadjuvant chemotherapy in oral squamous cell carcinoma |
| Q89066915 | Management of advanced hypopharyngeal carcinoma: systematic review of survival following surgical and non-surgical treatments |
| Q37705406 | Management of squamous cell carcinoma of the head and neck: updated European treatment recommendations. |
| Q46813073 | Mature results of neoadjuvant chemotherapy followed by radiotherapy in nasopharyngeal cancer: is it really old fashioned? |
| Q47106685 | Mechanisms underlying the antiproliferative effects of a series of quinoxaline-derived chalcones |
| Q36050759 | Molecular analyses of unselected head and neck cancer cases demonstrates that human papillomavirus transcriptional activity is positively associated with survival and prognosis. |
| Q53348920 | Multidisciplinary Symposium on Head and Neck Cancer. 2 December 2005, Philadelphia, PA, USA. |
| Q34142639 | Multimodal laryngeal preservation: current data-based opinion |
| Q35469234 | Nab-paclitaxel-based compared to docetaxel-based induction chemotherapy regimens for locally advanced squamous cell carcinoma of the head and neck |
| Q36051701 | Neoadjuvant chemotherapy and transoral surgery as a definitive treatment for oropharyngeal cancer: A feasible novel approach |
| Q43632373 | Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma: interim results from 2 prospective phase 2 clinical trials |
| Q90650174 | Neoadjuvant chemotherapy followed by surgery for HPV-associated locoregionally advanced oropharynx cancer |
| Q26768434 | Neoadjuvant chemotherapy in oral cancers: Selecting the right patients |
| Q46087306 | Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck |
| Q33310507 | Organ preservation in laryngeal and hypopharyngeal cancer |
| Q46534502 | Organ sparing treatment modalities - which type of treatment for which carcinoma? |
| Q37783681 | Palliation of Male Genital Cancers |
| Q82590340 | Penile Carcinoma: Treatment of Metastatic Disease after Previous Neoadjuvant Chemotherapy and Locoregional Therapy |
| Q38619293 | Pharmacotherapy of head and neck cancer |
| Q35611873 | Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC). |
| Q83864103 | Phase I/II docetaxel plus concurrent hyperfractionated radiotherapy in locally advanced unresectable head and neck cancer (TAX.ES1.102 study) |
| Q53042422 | Phase II organ-preservation trial: Concurrent cisplatin and radiotherapy for advanced laryngeal cancer after response to docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy. |
| Q33906160 | Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity-modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumours of the oro-, hypopharynx and larynx--TPF- |
| Q51754543 | Pleural metastases as a unique entity with dismal outcome of head and neck squamous cell carcinoma |
| Q35694837 | Prognostic Role of Circulating Tumor Cells during Induction Chemotherapy Followed by Curative Surgery Combined with Postoperative Radiotherapy in Patients with Locally Advanced Oral and Oropharyngeal Squamous Cell Cancer |
| Q36685556 | Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era. |
| Q37788244 | Radiotherapy for laryngeal squamous cell carcinoma: current standards |
| Q47282066 | Radiotherapy for locally advanced resectable T3-T4 laryngeal cancer-does laryngeal preservation strategy compromise survival? |
| Q98771228 | Randomized Controlled Study Comparing Efficacy and Toxicity of Weekly vs. 3-Weekly Induction Chemotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma |
| Q46007972 | Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma. |
| Q87671466 | Recent Landmark Studies on Head and Neck Cancers: Evidence-Based Fundamentals of Modern Therapeutic Approaches |
| Q37118936 | Recurrent head and neck cancer: current treatment and future prospects. |
| Q37026179 | Resistant metastatic penile carcinoma and response to biochemotherapy with paclitaxel and epidermal growth factor receptor monoclonal antibody, nimotuzumab |
| Q46496675 | Retrospective analysis of surgical resection after induction chemotherapy for patients with T4b squamous cell head and neck cancer. |
| Q38760427 | Revisiting induction chemotherapy before radiotherapy for head and neck cancer, part I: carcinoma of non-nasopharyngeal sites. |
| Q27022454 | Role of chemotherapy in nasopharyngeal carcinoma |
| Q33389563 | S-1 plus cisplatin: another option in the treatment of advanced head and neck cancer? |
| Q51644219 | SEOM clinical guidelines for the treatment of head and neck cancer |
| Q46335170 | SEOM clinical guidelines for the treatment of head and neck cancer (HNC) 2013. |
| Q40100374 | Score of liver ultrasonography predicts treatment-related severe neutropenia and neutropenic fever in induction chemotherapy with docetaxel for locally advanced head and neck cancer patients with normal serum transamines. |
| Q33518034 | Sensitive HPV detection in oropharyngeal cancers |
| Q40221340 | Sequential TPF chemotherapy followed by concurrent chemoradiotherapy in locally advanced head and neck cancer--a retrospective analysis of toxicity and outcomes |
| Q33380006 | Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer |
| Q35610879 | Sequential therapy (triple drug-based induction chemotherapy followed by concurrent chemoradiotherapy) in locally advanced inoperable head and neck cancer patients - Single institute experience |
| Q91015143 | Sequential therapy of neoadjuvant biochemotherapy with cetuximab, paclitaxel, and cisplatin followed by cetuximab-based concurrent bioradiotherapy in high-risk locally advanced oral squamous cell carcinoma: Final analysis of a phase 2 clinical trial |
| Q34620650 | Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. |
| Q37488983 | Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up |
| Q38855117 | Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review |
| Q38685473 | Systemic therapy in the curative treatment of head-and-neck squamous cell cancer: Cancer Care Ontario clinical practice guideline |
| Q36529843 | Systemic therapy strategies for head-neck carcinomas: Current status |
| Q40207325 | TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group |
| Q55644910 | TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. |
| Q40001262 | Tanshinone IIA induces apoptosis in human oral cancer KB cells through a mitochondria-dependent pathway |
| Q37149342 | Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications |
| Q79659062 | Taxane-based chemoirradiation for organ preservation with locally advanced head and neck cancer: results of a phase II multi-institutional trial |
| Q40374903 | Taxane-cisplatin-fluorouracil as induction chemotherapy for advanced head and neck cancer: a meta-analysis of the 5-year efficacy and safety |
| Q37002445 | Ten years of progress in head and neck cancers |
| Q35845864 | The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. |
| Q42852124 | The current value of induction chemotherapy. ASCO Congress 2010 |
| Q33386187 | The efficacy of an induction chemotherapy combination with docetaxel, cisplatin, and 5-FU followed by concurrent chemoradiotherapy in advanced head and neck cancer |
| Q34583677 | The impact of treatment modality and radiation technique on outcomes and toxicity of patients with locally advanced oropharyngeal cancer |
| Q35882999 | The role of chemotherapy in the management of patients with head and neck cancer |
| Q49882298 | The role of interim FDG PET-CT after induction chemotherapy as a predictor of concurrent chemoradiotherapy efficacy and prognosis for head and neck cancer |
| Q38030880 | The role of sequential chemoradiation for local advanced oropharyngeal carcinoma |
| Q53222097 | The role of technetium-99m methoxyisobutyl isonitrile scintigraphy in predicting the therapeutic effect of chemotherapy against nasopharyngeal carcinoma. |
| Q46425931 | Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia |
| Q38195513 | Treatment de-escalation in HPV-positive oropharyngeal carcinoma: ongoing trials, critical issues and perspectives |
| Q38958367 | Treatment of head and neck cancer in the elderly |
| Q33404307 | Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma |
| Q45366338 | Usefulness of Interim FDG-PET After Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Sequential Induction Chemotherapy Followed by Concurrent Chemoradiotherapy |
| Q40121235 | Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial |
| Q81287809 | [Combined modality approaches in the treatment of head and neck cancer patients] |
| Q84134378 | [Results of an organ conservation protocol in patients with locally advanced laryngeal tumours] |
| Q79853971 | [Transoral resection of locally advanced squamous cell carcinoma of the side wall of the oropharynx: multimodal treatment concepts in transition] |
Search more.